Taysha Gene Therapies Inc TSHA.OQ TSHA.O is expected to show a fall in quarterly revenue when it reports results on November 13 for the period ending September 30 2024
The Dallas Texas-based company is expected to report a 65.3% decrease in revenue to $1.648 million from $4.75 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
LSEG's mean analyst estimate for Taysha Gene Therapies Inc is for a loss of 9 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Taysha Gene Therapies Inc is $7.00, above its last closing price of $1.63.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.16 | -0.16 | -0.09 | Beat | 45.3 |
Jan. 1 2024 | -0.12 | -0.11 | -0.10 | Beat | 8.6 |
Jan. 1 0001 | -0.11 | 0.92 | Beat | 936.4 | |
Sep. 30 2023 | -0.19 | -0.17 | -0.13 | Beat | 24.7 |
Jun. 30 2023 | -0.31 | -0.31 | -0.38 | Missed | -22.1 |
Mar. 31 2023 | -0.36 | -0.35 | -0.28 | Beat | 20.9 |
Dec. 31 2022 | -0.42 | -0.33 | -0.34 | Missed | -3.3 |
Sep. 30 2022 | -0.81 | -0.82 | -0.64 | Beat | 21.6 |
This summary was machine generated November 12 at 03:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments